1. Home
  2. CPZ vs AGEN Comparison

CPZ vs AGEN Comparison

Compare CPZ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Long/Short Equity & Dynamic Income Trust

CPZ

Calamos Long/Short Equity & Dynamic Income Trust

HOLD

Current Price

$13.00

Market Cap

272.9M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.15

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPZ
AGEN
Founded
N/A
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
272.9M
147.4M
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
CPZ
AGEN
Price
$13.00
$3.15
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
85.0K
858.3K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.04
Revenue Growth
N/A
89.95
52 Week Low
$12.85
$2.71
52 Week High
$16.82
$7.34

Technical Indicators

Market Signals
Indicator
CPZ
AGEN
Relative Strength Index (RSI) 29.93 38.37
Support Level N/A $2.91
Resistance Level $15.13 $3.26
Average True Range (ATR) 0.23 0.26
MACD -0.06 -0.08
Stochastic Oscillator 15.98 10.39

Price Performance

Historical Comparison
CPZ
AGEN

About CPZ Calamos Long/Short Equity & Dynamic Income Trust

Calamos L/S Equity & Dynamic Inc Trust is a trust company that seeks to provide current income and risk-managed capital appreciation, with an investment objective to deliver total return through a combination of capital appreciation and current income. The Fund invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary, and others, and holds securities with a broad range of maturities, with the average term to maturity typically ranging from two to ten years. Managed assets represent the Fund's total assets, including any assets attributable to leverage that may be outstanding, minus total liabilities other than debt representing financial leverage.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: